Editas Medicine, Inc. 8-K

What Happened
Editas Medicine, Inc. announced on May 5, 2026 that it issued a press release reporting its financial results for the fiscal quarter ended March 31, 2026 and providing additional business highlights. The company furnished the press release as Exhibit 99.1 to its Form 8-K filed the same day. The Form 8-K was signed by Chief Financial Officer Amy Parison.

Key Details

• The 8-K was filed on May 5, 2026 and covers quarterly results for the period ended March 31, 2026.
• The company's press release is attached as Exhibit 99.1 to the Form 8-K (the exhibit is furnished, not filed).
• The report was signed by Amy Parison, Chief Financial Officer of Editas Medicine.

Why It Matters
This 8-K notifies investors that Editas has released its latest quarterly earnings and business update—information investors use to assess recent revenue, expenses, cash position and progress on product or pipeline milestones. Because the press release is furnished as an exhibit, investors should review that release directly for the specific financial figures and operational highlights disclosed for Q1 2026.